Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach

BACKGROUND: Small cell lung cancer (SCLC) is a highly malignant cancer characterized by metastasis and an extremely poor prognosis. Although combined chemoimmunotherapy improves the prognosis of extensive-stage (ES)-SCLC, the survival benefits remain limited. Furthermore, no reliable biomarker is av...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jie, He, Yayi, Yang, Xue, Tian, Panwen, Zeng, Liang, Huang, Kun, Zhao, Jing, Zhou, Jiaqi, Zhu, Yin, Wang, Qiyuan, Chen, Mailin, Li, Wen, Gao, Yi, Zhang, Yongchang, Xia, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514620/
https://www.ncbi.nlm.nih.gov/pubmed/37730276
http://dx.doi.org/10.1136/jitc-2023-007492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514620/
https://www.ncbi.nlm.nih.gov/pubmed/37730276
http://dx.doi.org/10.1136/jitc-2023-007492

Ejemplares similares